The first series A tranche will help commercialise a remedy for metabolic disorders and inflammatory conditions resulting from cardio-metabolic problems.

Cambridge spinout Crescendo Biologics has secured $70m in an IP Group and EMBL Ventures-backed round.

The accelerator will connect AbbVie scientists with the lab of Kyriacos Nicolaou, pioneer of an approach for replicating natural molecules with cancer-fighting qualities.

The UCL spinout has secured an additional licence to a protein that aims to reduce side effects associated with its Car T immuno-oncological approach.

Iluminos will commercialise compounds with the potential to combat neurodegenerative diseases such as Alzheimer's.

A round up of all the latest news on www.globaluniversityventuring.com for our subscribers.

GraphicsFuzz will launch a security testing tool for graphics drivers to catch potential flaws using a metamorphic approach.

Harvard University has spun out NuProbe to commercialise a molecular blood test based on research by Peng Yin and David Zhang at the Wyss Institute.